PRESS RELEASE published on 04/17/2023 at 08:00, 1 year 7 months ago Defence Therapeutics Inc.: DEFENCE'S NOVEL ACCUMTM-mRNA VACCINE NOW ADMINISTERED FOR TESTING ON CANCER
PRESS RELEASE published on 04/11/2023 at 08:00, 1 year 7 months ago DEFENCE BREAKTHROUGH: SUCCESSFULLY ENGINEERED ACCUM(TM) -mRNA VACCINE CREATING A NEW VACCINE PLATFORM. THE IN VIVO ACCUM(TM)-mRNA CANCER VACCINE PROGRAM BEGINS
PRESS RELEASE published on 03/28/2023 at 08:00, 1 year 7 months ago DEFENCE TO COMPLETE A FINAL PRE-CLINICAL STUDY PRIOR TO IND FILINGS FOR THE ACCUTOXTM PHASE I CANCER TRIAL AT THE CITY OF HOPE NATIONAL MEDICAL CENTER AND BECKMAN RESEARCH INSTITUTE
PRESS RELEASE published on 03/14/2023 at 08:00, 1 year 8 months ago DEFENCE THERAPEUTICS SIGNS COLLABORATION AGREEMENT WITH ORANO TO DEVELOP THE NEXT GENERATION OF TARGETED RADIO-IMMUNOTHERAPY FOR CANCER
PRESS RELEASE published on 02/27/2023 at 08:00, 1 year 8 months ago DEFENCE’S PIPELINE ADVANCES TO MULTIPLE PHASE I CLINICAL TRIALS
PRESS RELEASE published on 02/21/2023 at 08:00, 1 year 9 months ago Defence Therapeutics Inc.: DEFENCE DELEGATES CITY OF HOPE TO INITIATE IND FILLING FOR ITS ACCUTOXTM CANCER PROGRAM
PRESS RELEASE published on 02/06/2023 at 08:00, 1 year 9 months ago DEFENCE MANUFACTURING ITS ARM VACCINE IN PREPARATION FOR PHASE I CLINICAL TRIAL AGAINST SOLID TUMORS
PRESS RELEASE published on 02/03/2023 at 08:00, 1 year 9 months ago DEFENCE THERAPEUTICS AND CQDM FUND THE DEVELOPMENT OF A NEW CANCER VACCINE PLATFORM
PRESS RELEASE published on 01/31/2023 at 08:00, 1 year 9 months ago Defence Therapeutics Inc.: DEFENCE’S LUNG CANCER GLP TOX STUDY ON ITS INTRANASAL ACCUTOXTM FORMULATION ADVANCES
PRESS RELEASE published on 01/24/2023 at 08:00, 1 year 9 months ago DEFENCE’S MELANOMA TARGETED VACCINE A1-REPROGRAMMED MSC (ARM) CELL POTENCY VALIDATED
Published on 11/22/2024 at 09:00, 3 hours 14 minutes ago Industrial Software Company mlean Celebrates 10 Years of Continuous Improvement
Published on 11/22/2024 at 00:00, 12 hours 14 minutes ago Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 14 hours 9 minutes ago Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 14 hours 24 minutes ago Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 15 hours 59 minutes ago Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/22/2024 at 11:54, 20 minutes ago PIERER Mobility denies media reports about Mark Mateschitz's participation in PIERER Mobility and KTM
Published on 11/22/2024 at 11:45, 29 minutes ago How 5G Transforms Life: A Foreigner's Journey Through East China's Digital Revolution
Published on 11/22/2024 at 11:21, 53 minutes ago Original-Research: ParTec AG (von First Berlin Equity Research GmbH): Buy
Published on 11/22/2024 at 11:06, 1 hour 8 minutes ago Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 06:58, 1 day 5 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 16 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 18 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 18 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 2 days 4 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
